6Y1 Stock Chart & Stats
€0.94
-€0.06(-3.43%)
At close: 4:00 PM EST
€0.94
-€0.06(-3.43%)
Day’s Range― - ―
52-Week Range€0.59 - €1.16
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€21.16M
Enterprise Value€221.88M
Total Cash (Recent Filing)€15.01M
Total Debt (Recent Filing)€2.74M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Dec 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding26,027,910
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)1.07
Price to Sales (P/S)2.01
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.06
Revenue Forecast (FY)€19.29M
Bulls Say, Bears Say
Bulls Say
Specialized Osseointegration PlatformIntegrum operates in a specialized medtech niche with an implant platform designed to improve comfort and mobility versus traditional socket prostheses. This focused clinical use case can support durable demand as patients and healthcare providers seek alternatives for long-term prosthetic attachment.
Meaningful Revenue GrowthMeaningful revenue expansion indicates that Integrum has continued to increase commercial activity despite its profitability challenges. Sustained growth can broaden the installed patient base, support greater provider adoption, and create a larger foundation for operating leverage if costs become better controlled.
Very Low Financial LeverageThe conservative capital structure reduces solvency pressure and gives Integrum more flexibility while it works to improve operations. Very low leverage also limits interest-related strain, allowing future capital allocation to focus more directly on clinical development, commercialization, and restoring profitability.
Bears Say
Severe Current Profitability PressureNegative gross profit and deeply negative operating and net margins indicate that current sales are not covering the cost base. This limits internal funding capacity and means revenue growth may not translate into durable earnings until pricing, product economics, or expense discipline improves.
Persistent Cash BurnOngoing operating and free-cash-flow deficits increase dependence on available funding and make execution more sensitive to delays in reaching profitability. Continued cash burn can constrain investment choices over the next several quarters even though the balance sheet currently carries low debt.
Unstable Earnings RecordThe shift from profitability to sizeable losses across recent periods shows that earnings performance is not yet dependable. This instability raises execution risk because management must demonstrate that growth can be converted into repeatable margins rather than intermittent profits.
Integrum AB Class B News
6Y1 FAQ
What was Integrum AB Class B’s price range in the past 12 months?
Integrum AB Class B lowest stock price was €0.59 and its highest was €1.16 in the past 12 months.
What is Integrum AB Class B’s market cap?
Integrum AB Class B’s market cap is €21.16M.
When is Integrum AB Class B’s upcoming earnings report date?
Integrum AB Class B’s upcoming earnings report date is Dec 03, 2026 which is in 59 days.
How were Integrum AB Class B’s earnings last quarter?
Integrum AB Class B released its earnings results on Sep 03, 2026. The company reported €0.003 earnings per share for the quarter.
Is Integrum AB Class B overvalued?
According to Wall Street analysts Integrum AB Class B’s price is currently Overvalued.
Does Integrum AB Class B pay dividends?
Integrum AB Class B does not currently pay dividends.
What is Integrum AB Class B’s EPS estimate?
Integrum AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Integrum AB Class B have?
Integrum AB Class B has 26,027,910 shares outstanding.
What happened to Integrum AB Class B’s price movement after its last earnings report?
Integrum AB Class B reported an EPS of €0.003 in its last earnings report. Following the earnings report the stock price went up 10.308%.
Which hedge fund is a major shareholder of Integrum AB Class B?
Currently, no hedge funds are holding shares in DE:6Y1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Integrum AB Class B
Integrum AB (publ) focuses on the research, development, and global sale of advanced bone-anchored prosthetic solutions. A core offering is the Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant system. This innovative bone-anchored prosthesis integrates directly with the patient's bone through osseointegration, thus circumventing the need for a conventional socket. A significant benefit of the OPRA system is its protective quality, helping to prevent bone fractures from accidental loads. Additionally, Integrum provides Neuromotus, a therapeutic technology designed to mitigate phantom limb pain following an amputation. These sophisticated implant systems are distributed worldwide to hospitals, clinics, and orthopedic professionals. The company was founded in 1962 and is based in Mölndal, Sweden.